AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06009692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper limb Neuro-dynamics (Slider/ Tensioner Technique)
Description: The experimental group will receive neuro-dynamic mobilization techniques along with task oriented training. Slider versus tensioner technique will be applied according to each patient's need. Session time will be 25-30 minutes. Four series of 10 tensioning movements at a rhythm of ∼6s per cycle and 1 min rest between each series will be performed. After each cycle of 10 repetitions, the position will hold for 10s.
Study NCT06009692 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy for Upper limb
Description: Conventional treatment will include therapeutic ultrasound for 4 min, TENS for 10 min. Task oriented training will be designed according to patient's functional outcomes. Sessions will be given for 6 days a week, 25-30 minutes per day.
Study NCT06558461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Sodium Chloride
Description: 4ml nebulized three times daily
Study NCT05420272 — intervention group
Intervention type: BEHAVIORAL
Intervention: Trunk performance and endurance lower extremity biomechanic
Description: Trunk performance and endurance lower extremity biomechanic
Study NCT06558461 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care
Study NCT04960566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The CBT intervention is based on the theoretical framework that under stress (reflux symptoms) a person makes a rapid cognitive appraisal of the potential threat (automatic thoughts), leading to both emotional and physical responses in the body, thereby reacting behaviorally (avoidance, increased HCU) in an attempt to mitigate unpleasantness. CBT is a collaborative, present-focused treatment that utilizes a skills-based approach with home practice exercises. CBT targets automatic thoughts and appraisals of threat via education, self-monitoring of stressors and symptoms, and strategies to reframe problematic thinking patterns to more adaptive ones. Resonance frequency breathing (RFB) is achieved when a person breathes at a pace, typically 4 to 6 breaths per minute, that engages the body's baroreflex to modulate arousal. Prior research demonstrates 4 to 6 weeks of RFB training is sufficient to significantly increase baseline HRV with enduring effects for up to 6 months.
Study NCT04960566 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-SOC Lifestyle Coaching
Description: Sham-SOC Lifestyle Coaching
Study NCT05965817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGM-101 op top of ICG
Description: SGM-101 op top of ICG
Study NCT05845957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Education Group
Description: Providing training on safe pediatric intravenous drug administration with digital storytelling method
Study NCT06283121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioTTT001 intraperitoneal infusion
Description: Monotherapy lead-in phase: BioTTT01 1×10\^10 VP, i.p., D1 and D3; Combination therapy phase: BioTTT01 1×10\^10 VP, i.p., D1 and D3, 3 weeks per cycle
Study NCT06283121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX regimen
Description: Combination therapy phase: Oxaliplatin 130 mg，i.v., D1 and D3, 3 weeks per cycle; Tegafur 40\~60mg b.i.d. p.o. D1\~D14; 3 weeks per cycle
Study NCT06283121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toripalimab
Description: Combination therapy phase: toripalimab 160mg i.v. D1, 3 weeks per cycle.
Study NCT05527158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yi Jin Jing exercise
Description: Yi Jin Jing of The General Administration of Sport of China, which consists of twelve operational processes as the standard intervention
Study NCT06550128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHB-137 injection
Description: AHB-137 injection will be administered subcutaneously.
Study NCT06550128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AHB-137 injection
Description: AHB-137 injection will be administered subcutaneously.
Study NCT06550128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered subcutaneously.
Study NCT06550128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.
Study NCT06160167 — intervention group
Intervention type: DRUG
Intervention: IMiD treatment
Description: Participants with MM treated with IMiDs
Study NCT06160167 — intervention group
Intervention type: DRUG
Intervention: No IMiD treatment
Description: Participants with MM not treated with IMiDs
Study NCT06160167 — intervention group
Intervention type: DRUG
Intervention: Systemic therapy
Description: Participants with MM treated with systemic therapy
Study NCT06637124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Therapy Device
Description: Blood Flow Restriction (BFR) therapy involves units use standardized cuffs of varying widths and lengths which are physically attached to the devices and provide the capability of precisely controlling the amount of pressure applied to each limb during exercise or at rest.~We will be using Smart Cuffs® 4.0 which allows for a fast, hassle-free personalized pressure calculation. With the built-in pressure sensor and on-board computer, it will calculate and set the optimal pressure for each participant's limb. There is no need for an external doppler probe or hand pump. Made in the USA, SmartCuffs® are registered with the FDA as a Class 1 Medical Device.~Blood flow restriction therapy is commonly paired with resistive training, so this study will explore the effect of blood flow restriction at rest for patients with osteoarthritis at different restriction levels (50% for first group and 70% for second group).
Study NCT06637124 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 45° leg-press machine, 90°-0° of knee flexion knee extension machine, leg curl machine and calf raise machine.
Description: Patients assigned to group will receive strengthening of the lower limb musculature through moderate intensity resistance training (60% of 1RM) using a 45° leg-press machine, 90°-0° of knee flexion knee extension machine, leg curl machine and calf raise machine.
Study NCT06645223 — intervention group
Intervention type: DRUG
Intervention: No Interventions
Description: no interventions
Study NCT06639009 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 940nm diode laser photobiomodulation
Description: The surgical handpiece (diameter 0.6cm) will be used without the fibre optic tips in defocused mode and head sanitized before therapy.~Peak Power : 0.3Watts Power density: 1 Watt/cm2 Fluence: 4J/cm2 per cycle Spot size : 0.28cm2 Distance : 2mm from surface Mode: Continuous, Non- contact mode, circular motion, overlapping, in clockwise concentric manner with laser handpiece perpendicular to surface Duration of cycle : 25 seconds with interval of 30 seconds alternating with other side Cycles per sitting: Four for each side Four Sittings: Day 0,3, 7, and 15 Area of intervention: Bilateral buccal mucosa and masseter muscle Total treatment time per day: 430 seconds/ approx 7 minutes Total treatment time for 4 sittings: approx 28 minutes
Study NCT05252624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet manufactured to mimic henagliflozin 5 mg tablet
Study NCT04757246 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MouthLab Device
Description: Use of MouthLab system
Study NCT06462885 — intervention group
Intervention type: BEHAVIORAL
Intervention: home support, hiving alone
Description: Home support: living alone
Study NCT06462885 — intervention group
Intervention type: BEHAVIORAL
Intervention: home support, living with others
Description: Home support: living with others
Study NCT06639009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 940nm diode laser photobiomodulation
Description: The surgical handpiece (diameter 0.6cm) will be used without the fibre optic tips in defocused mode and head sanitized before therapy.~Peak Power : 0.3Watts Power density: 1 Watt/cm2 Fluence: 4J/cm2 per cycle Spot size : 0.28cm2 Distance : 2mm from surface Mode: Continuous, Non- contact mode, circular motion, overlapping, in clockwise concentric manner with laser handpiece perpendicular to surface Duration of cycle : 25 seconds with interval of 30 seconds alternating with other side Cycles per sitting: Four for each side Four Sittings: Day 0,3, 7, and 15 Area of intervention: Bilateral buccal mucosa and masseter muscle Total treatment time per day: 430 seconds/ approx 7 minutes Total treatment time for 4 sittings: approx 28 minutes
Study NCT06639009 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional non -Invasive management in Oral Submucous fibrosis
Description: Brief behavioral Tobacco, areca nut and alcohol habit cessation counseling as per WHO 5As and 5Rs technique at baseline and each follow up.~Oral prophylaxis Removal of oral irritational factors like sharp teeth, appliances or prosthesis, impacted buccoverted third molars, parafunctional habits Oral hygiene maintenance instructions Oral physiotherapy Control of systemic conditions Removal of all predisposing factors for oral candida infection Advocacy for safe sexual practices Nutrition and diet counseling( seasonal and regional food rich in nutrients, vitamins, antioxidants avoidance of spicy /sour/ hot foods and drinks) Regular surveillance for malignant transformation
Study NCT06639009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional non -Invasive management in Oral Submucous fibrosis
Description: Brief behavioral Tobacco, areca nut and alcohol habit cessation counseling as per WHO 5As and 5Rs technique at baseline and each follow up.~Oral prophylaxis Removal of oral irritational factors like sharp teeth, appliances or prosthesis, impacted buccoverted third molars, parafunctional habits Oral hygiene maintenance instructions Oral physiotherapy Control of systemic conditions Removal of all predisposing factors for oral candida infection Advocacy for safe sexual practices Nutrition and diet counseling( seasonal and regional food rich in nutrients, vitamins, antioxidants avoidance of spicy /sour/ hot foods and drinks) Regular surveillance for malignant transformation
Study NCT05252624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Henagliflozin 5Mg Tab
Description: Single oral tablet
Study NCT05002309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioural Therapy
Description: 20 sessions of individual CBT are offered over 16 weeks, conducted 1-on-1, with a trained and supervised therapist. Participants will learn about the cognitive, behavioural, emotional, and environmental factors which contribute to maintaining their depression. They will apply skills to interrupt unhelpful cognitive and behavioural patterns and engage in guided exploration to improve self-understanding. CBT is a structured and collaborative treatment. Weekly homework will be used to maximize opportunities for practice and consolidation of new skills. The individual sessions can be combined with optional family/parent/partner sessions, depending on the situation and preferences of the participant. All sessions will be video-recorded to allow high-quality supervision, fidelity- and quality-assurance. This corresponds to evidence available for CBT for adolescents and young adults that is established as the best practice through rigorous trials.
Study NCT05002309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Description: The choice of antidepressants follows best-established evidence for treating depression in adolescents and young adults. We will offer treatment with fluoxetine, starting at 10mg a day, increasing to 20mg a day after 1 week if tolerated; a protocol established as safe and effective in adolescents and adults in multiple trials. Additional increases to 40 or 60mg will be possible based on positive effects and side-effects and clinical judgement, as recommended in this age group. In cases of intolerance or adverse reaction to fluoxetine, we will switch to sertraline (25-200mg) or escitalopram (5-20mg), two antidepressants licensed by the FDA for major depressive disorder in adolescents. Treatment will be optimized over 16 weeks, a time-frame comparable to the CBT arm. Pharmacotherapy will be managed and prescribed by qualified psychiatrists when starting treatment and reviewed after 1 week, 2 weeks and then in 2-weekly intervals for the remainder of the 16 weeks acute treatment period.
Study NCT06125405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: The study duration was 52 weeks, with the experimental group receiving subcutaneous injections of Telitacicept once weekly for a total of 52 weeks.
Study NCT06073067 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: GRID therapy
Description: GRID therapy delivers a high dose of radiation to small areas of tumor interleaved with areas that intentionally receive a low dose
Study NCT05031897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT05031897 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT05031897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion
Description: Undergo DLI
Study NCT05031897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT05031897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV
Study NCT05031897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV
Study NCT05031897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo HSCT
Study NCT05031897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT05031897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration/ biopsy
Study NCT05031897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo diagnostic imaging
Study NCT05031897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04254627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 50 mg weekly injection
Study NCT04254627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 300 mg pill
Study NCT06567847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurocognitive Enriched Exercise
Description: An intervention planned, progressed, and conducted under the supervision of a physiotherapist, which enriches strengthening, balance, range of motion, stretching, and mobilization exercises with neurocognitive elements.
Study NCT06567847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Exercise
Description: Supervised and progressively advanced interventions that include strengthening, balance, range of motion, stretching, and mobilization exercises.
Study NCT04629196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: A second IV weight-based induction dose of Stelara at week 8
Study NCT04629196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: A standard 90mg subcutaneous dose of Stelara at week 8
Study NCT04629196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: All patients will receive IV ustekinumab weight-based dose at 260mg (55kg or less), 390mg (more than 55kg to 85kg), or 520mg (more than 85kg) at time point 0
Study NCT04629196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: All patients will receive IV ustekinumab weight-based dose at 260mg (55kg or less), 390mg (more than 55kg to 85kg), or 520mg (more than 85kg) at time point 0
Study NCT04852588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA)
Description: Chest lymph node sampling procedure by EBUS
Study NCT04852588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transesophageal ultrasound-guided fine needle aspiration (EUS-FNA)
Description: Chest lymph node sampling procedure by EUS
Study NCT05785117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagal Stimulation
Description: ear clips were placed in the ear region (auricular concha) at the stimulation site. The following stimulation settings were used: 1) density wave set to 20 Hz with a wave width of less than 1 ms; 2) intensity tuned to the patient's tolerance (4-6 mA)
Study NCT05785117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit training program
Description: The training regimen included ten different forms of resistance and aerobic exercise that were done three times a week for four weeks. The resistance training program included push-ups, squats, crunches, lunges, and a superman exercise program that included light jumping, jogging on the spot, foot stomping, steps, and jumping jacks
Study NCT05837676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Training for Concussion
Description: PST-Concussion is a combined treatment consisting of brief problem-solving training, standard concussion education, motivational interviewing, goal-setting, and compensatory cognitive strategies.
Study NCT05837676 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Patients assigned to TAU will receive the care that they and their providers determine is necessary to best manage their presenting concerns.
Study NCT06555029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EHR Changes
Description: Practice-Level:~Changes to the Epic EHR system will include the AAAC process to ask 5 oral health questions, advise for dental attendance, assess the type of referral, and connect with referral and resources
Study NCT06555029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Staff EHR Training, Clinician CSM theory-based didactic education and skills training
Description: Provider-Level:~Medical staff to complete EHR training and then deliver the ask, advise, assess, connect (AAAC) strategies to screen, refer, and provide resources for oral health.~Clinician will receive Common-Sense Model of Self- Regulation (CSM) and Social Cognitive Theory based education and skills training for the physician/nurse practitioner to communicate core OH facts to the patient and provide reinforcement of the importance of dental visits to overall health. Clinicians will also document the encounter in EHR.
Study NCT06555029 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard ADA Oral Health Training
Description: Provider-Level:~Clinician only: Clinicians will receive standard American Dental Association (ADA) based oral health hygiene training (brushing, flossing, fluoridated water, cleaning dentures) and asked to follow their current oral health care with their patients. The usual care currently is to address oral health issues if the patient complains or has a question. The clinicians will not have skills training nor visual resources for the patient encounter.
Study NCT05506930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine
Description: One group of subjects will receive intrathecal morphine: spinal (neuraxial) dose of preservative free morphine (Duramorph), usually about 4-5mcg/kg. This is injected into the cerebrospinal fluid under sterile technique by a pediatric anesthesiologist while the subject is already under general anesthesia. This procedure is well-described in the pediatric population and used regularly for postoperative pain relief for a variety of procedures including ureteral reimplantation.
Study NCT05506930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block
Description: The second group of subjects will have bilateral quadratus lumborum blocks: peripheral nerve block utilizing ropivacaine 0.2%, usually about ½ mL per/ kg per side (total dose approximately 1mL/kg). This is injected in the subject's flank in the fascial plane between the quadratus lumborum muscle and the psoas muscle. Ultrasound guidance is used for needle and structure localization and this procedure is done by a pediatric anesthesiologist while the subject is already under general anesthesia. Quadratus lumborum blocks are regularly used in clinical practice for postoperative pain relief for a variety of abdominal procedures.
Study NCT04753463 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: The on-line questionnaire which assess the subjective feelings of residents of pandemic impact on ophthalmology training programs
Study NCT04158635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Given PO
Study NCT05113927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selene
Description: SELENE imaging of all margins, with record of each margin assessment and an opportunity to excise tissue from the lumpectomy cavity post-imaging. The new margin will be imaged with SELENE and the surgeon will record the assessment and may take additional tissue (up to a maximum of six total shaves, including up to two shaves in each orientation) or record why no further tissue may be taken.
Study NCT05037851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opelconazole
Description: Nebulizer suspension
Study NCT05037851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care